Figure 4

Combination of circulating tumor cell (CTC) status at baseline and known clinicopathologic risk factors, extracapsular extension (ECE) or seminal vesicle invasion (SVI), can predict for time to biochemical failure following adjuvant or salvage radiotherapy. (a) Percentage of patients who are biochemical failure free over a 36-month period and who presented with ECE, but without CTCs (CTC^neg/-; n=34), versus patients with ECE, but with CTCs (CTC^pos/+; n=4), at baseline (P=0.027). (b) Percentage of patients who are biochemical failure free over a 36-month period and who presented with positive margins (margins), but CTC^neg (n=29), versus patients with positive margins, but CTC^pos (n=2), at baseline (P>0.05). (c) Percentage of patients who are biochemical failure free over a 36-month period and who presented with SVI, but CTC^neg (n=5), versus patients with SVI, but CTC^pos (n=3), at baseline (P=0.043).